Private Capital Advisors Inc. Increases Stock Position in PTC Therapeutics, Inc. $PTCT

Private Capital Advisors Inc. raised its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 81.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 29,113 shares of the biopharmaceutical company’s stock after purchasing an additional 13,051 shares during the quarter. Private Capital Advisors Inc.’s holdings in PTC Therapeutics were worth $2,211,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in PTCT. Vanguard Group Inc. grew its stake in shares of PTC Therapeutics by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company’s stock worth $668,691,000 after purchasing an additional 514,204 shares during the period. Wellington Management Group LLP grew its stake in shares of PTC Therapeutics by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock worth $301,856,000 after purchasing an additional 224,481 shares during the period. State Street Corp lifted its stake in shares of PTC Therapeutics by 22.1% in the second quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock valued at $146,347,000 after purchasing an additional 541,558 shares during the period. Jefferies Financial Group Inc. lifted its stake in shares of PTC Therapeutics by 4.7% in the fourth quarter. Jefferies Financial Group Inc. now owns 1,658,481 shares of the biopharmaceutical company’s stock valued at $125,978,000 after purchasing an additional 73,803 shares during the period. Finally, UBS Group AG lifted its stake in shares of PTC Therapeutics by 113.3% in the fourth quarter. UBS Group AG now owns 964,658 shares of the biopharmaceutical company’s stock valued at $73,275,000 after purchasing an additional 512,449 shares during the period.

PTC Therapeutics Price Performance

Shares of NASDAQ:PTCT opened at $68.81 on Friday. The business’s 50 day simple moving average is $69.00 and its 200-day simple moving average is $72.41. The firm has a market capitalization of $5.71 billion, a price-to-earnings ratio of -29.53, a price-to-earnings-growth ratio of 12.83 and a beta of 0.53. PTC Therapeutics, Inc. has a 12 month low of $43.17 and a 12 month high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.42. The business had revenue of $272.55 million for the quarter, compared to analyst estimates of $217.42 million. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.The company’s quarterly revenue was up 43.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $10.04 EPS. On average, equities analysts anticipate that PTC Therapeutics, Inc. will post 0.19 earnings per share for the current year.

Insider Buying and Selling at PTC Therapeutics

In related news, CEO Matthew B. Klein sold 12,572 shares of PTC Therapeutics stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $72.95, for a total transaction of $917,127.40. Following the completion of the transaction, the chief executive officer directly owned 393,998 shares in the company, valued at $28,742,154.10. The trade was a 3.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Lee Scott Golden sold 829 shares of PTC Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $67.99, for a total value of $56,363.71. Following the transaction, the executive vice president owned 79,115 shares of the company’s stock, valued at $5,379,028.85. This represents a 1.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 115,022 shares of company stock worth $7,925,979. Corporate insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

PTCT has been the subject of several recent analyst reports. Barclays reiterated an “overweight” rating and issued a $120.00 price objective on shares of PTC Therapeutics in a research note on Monday, February 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of PTC Therapeutics in a research note on Friday, February 20th. Jefferies Financial Group lowered PTC Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $91.00 to $76.00 in a research note on Monday, March 30th. Morgan Stanley reissued an “overweight” rating and set a $94.00 price target on shares of PTC Therapeutics in a research note on Friday, May 8th. Finally, Raymond James Financial began coverage on PTC Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $108.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $88.36.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.